Core Viewpoint - Large-cap biotech stocks are considered resilient to disruption risks typically faced by tech companies, primarily due to their long drug approval processes and established product portfolios [1][2] Group 1: Biotech Sector Resilience - Companies like Amgen and AbbVie are highlighted for their ability to navigate revenue erosion through broad product portfolios and multi-year pipeline replacements [1] - The FDA approval process, which can take a decade, provides a structural time buffer that protects biotech firms from rapid obsolescence [1] - Year-to-date performance shows Amgen up 16% and Gilead up 21% in 2026, significantly outperforming the iShares Biotechnology ETF, which is up approximately 3% [1] Group 2: Disruption Mechanisms - While biotech firms are insulated from AI-driven disruption, they face challenges such as patent cliffs, biosimilar competition, and government drug pricing reforms [1] - AbbVie’s Humira lost exclusivity, leading to a revenue drop of about 50% in two years, highlighting the risks associated with patent cliffs [1] - Amgen's revenue from Enbrel fell 48% in Q4 2025 due to biosimilar competition and Medicare redesign, indicating structural revenue erosion [1] Group 3: Company-Specific Insights - Gilead's ASCENT-07 trial for Trodelvy missed its primary endpoint, demonstrating how clinical trial failures can significantly impact pipeline value [2] - Eli Lilly's stock has appreciated approximately 416% over five years, driven by the success of its GLP-1 products, but it is down 6% year-to-date in 2026 [2] - Biogen's revenue is expected to decline mid-single digits in 2026, with its MS franchise down 14% in Q4 2025, reflecting a different risk profile compared to other biotech firms [2] Group 4: Evaluating Biotech Stocks - Investors should assess biotech stocks based on three questions: the percentage of revenue from products with patent protection beyond five years, the presence of at least two Phase 3 pipeline products, and the strength of the balance sheet to support pipeline investments [2] - Amgen's CEO expressed confidence in the company's broad portfolio and innovative therapies, indicating a path for sustained long-term growth [2] - Understanding the specific types of disruption, such as patent cliffs and pricing reform, is crucial for investors to navigate volatility in the biotech sector [2]

Equity markets have been volatile this year, and market downturns have a way of testing even the most confident investors. Amid geopolitical tensions and lingering tariff-related uncertainty, some fear the stock market could take a turn for the worse by the end of the year, though no one can know for sure. But history shows that some of the best long-term investment opportunities emerge precisely when uncertainty is at its highest. Will AI create the world's first trillionaire? Our team just released a r ...

Harbor Capital is an asset manager focused on curating an intentionally select suite of active ETFs that they believe have the potential to produce compelling, risk-adjusted returns within a portfolio. Note: This account is not managed or monitored by Harbor Capital, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use Harbor Capital's official channels. ...

2026年3月9日，艾伯维发布了其Amylin类似物ABBV-295的最新一期临床数据：经过12周每周给药，受试者的体重最小二乘平均降幅达-7.75% 至-9.79%。到了第13周，剂量调整为每两周或每月给药后，体重降幅为-7.86%至-9.73%，远远超过安慰剂组的-0.26%与-0.25%。 尽管数据略显平稳，ABBV-295的初步结果还是展现了该药物在减重领域的强劲潜力。与同类药物相比，ABBV-295的早期疗效超越了罗氏的 petrelintide及诺和诺德的Cagrilintide。但在安全性方面，ABBV-295仍需改进，尤其是在胃肠道副作用方面。相比之下，petrelintide的耐受性 表现更佳，恶心发生率较低。 | Cohorta | LS Mean (95% CI) at week 12º | LS Mean (95% Cl) at week 130 | | --- | --- | --- | | All Placebo | -0.26 (-1.89, 1.37) | -0.25 (-1.88, 1.38) | | Cohort 3 (weekly dosing) | -7.75 (-9. ...

Question-and-Answer SessionMaybe, Scott, you can kick us off with some high-level remarks on the company's growth prospects and how we should think about the margin profile in coming years?Scott ReentsExecutive VP & CFO Yes, of course, happy to do that. First, thank you very much for having us down and beautiful weather. So it's never hard to come down here from Chicago at this time of the year. So I appreciate you having us. When we think about the business, I think we've been pretty -- we've talked a lot ...

AbbVie 2026 Conference Call Summary Company Overview - **Company**: AbbVie (NYSE: ABBV) - **Date**: March 10, 2026 - **Key Executives**: Roopal Thakkar (CSO), Scott Reents (CFO) Key Points Growth Prospects - AbbVie anticipates a revenue of **$67 billion in 2026**, reflecting strong growth momentum from 2025 [2][3] - The company expects to achieve **high single-digit growth** through the decade, supported by a robust portfolio of assets [2][3] Product Performance - **SKYRIZI and RINVOQ** have shown a combined growth of over **20%** in the past year, indicating strong market performance [3] - The company has significant room for market share growth, particularly in immunology and neuroscience [4] - The oral CGRPs for migraine, **UBRELVY and QULIPTA**, are projected to exceed **$5 billion** in peak sales [5] Financial Performance - AbbVie has expanded its operating margin, with **EPS growth exceeding 13%** and top-line growth just under **10%** [6] - The company continues to invest in R&D, maintaining a budget of **14%-15%** of revenue, which has increased by a few billion since 2022 [6] Competitive Landscape - SKYRIZI holds **60%** of new patient starts in IBD, with **75%** share among naive patients, indicating strong competitive positioning despite concerns about Tremfya [11][12] - The label update for RINVOQ allows for more flexible prescribing, enhancing its competitive edge in the market [14] Pipeline and Future Catalysts - Upcoming readouts include: - **RINVOQ** in Hidradenitis Suppurativa (HS) and combination studies in IBD [44][45] - **Lutikizumab**, targeting IL-1 alpha and beta, with potential for significant market impact in HS [44] - **T-cell engaging BCMA antibody** in multiple myeloma, expected to show a favorable safety profile [46] - **Gilgamesh asset** in depression, with potential expansion into PTSD [48] M&A and Business Development - AbbVie has conducted over **30 transactions** totaling approximately **$8 billion** in the last two years to enhance its R&D capabilities [63] - The company is open to pursuing quality assets that align with its long-term growth strategy, despite not needing immediate M&A [62][64] Market Positioning - AbbVie is focused on maintaining a strong financial discipline and providing detailed guidance to investors, which sets it apart from competitors [54][56] - The company is positioned for solid growth, with a low P/E-to-growth ratio indicating potential undervaluation in the market [58][61] Additional Insights - The company is optimistic about the efficacy of its new drug candidates, particularly in under-penetrated markets like HS and IBD [71] - AbbVie aims to optimize its pipeline with a focus on combination therapies and innovative treatment approaches [64][65] This summary encapsulates the key insights from AbbVie's conference call, highlighting the company's growth strategies, product performance, financial health, competitive landscape, and future opportunities.

Core Insights - AbbVie Inc. is a leading global biopharmaceutical company known for its innovative medicines, including Humira, and competes with major pharmaceutical companies like Pfizer and Merck [1] Stock Performance - AbbVie's stock has experienced a modest gain of 1.88% over the past month, with a slight decline of 0.43% in the last 10 days, indicating a potential strategic entry point for investors [2][6] - The estimated stock price increase of 12.62% suggests significant upside potential, with a target price of $256.15 indicating that the stock is currently undervalued [3][6] Financial Health - AbbVie's Piotroski Score of 8 reflects strong financial health, highlighting robust profitability, liquidity, and operational efficiency, reinforcing its attractiveness as an investment [4][6] Investment Opportunity - Given the recent performance trends, AbbVie may have reached a local minimum, presenting an opportune moment for investors to consider adding the stock to their portfolios for potential recovery and growth [5]

Core Viewpoint - The global pharmaceutical industry is experiencing a new competitive landscape as multinational companies release their 2025 performance reports, with Johnson & Johnson leading in total revenue at $94.193 billion, followed by Eli Lilly with a remarkable growth rate of 44% [1][2]. Group 1: Financial Performance of Major Pharmaceutical Companies - Johnson & Johnson achieved total revenue of $94.193 billion, with its innovative pharmaceuticals and medical technology segments generating $60.401 billion (+6%) and $33.792 billion (+6.1%) respectively [2]. - Eli Lilly reported a total revenue of $65.179 billion, marking a significant growth of 44% [2]. - Roche, Merck, Pfizer, AbbVie, AstraZeneca, and Novartis also showed upward revenue trends, contributing to the steady growth of the global pharmaceutical industry [1][2]. Group 2: Strategic Adjustments and Leadership Changes - Sanofi appointed Belén Garijo as the new CEO, focusing on enhancing the productivity and innovation capabilities of the R&D department [3]. - Merck announced a reorganization of its pharmaceutical business into two segments: oncology and specialty, aiming to maintain its leadership in cancer treatment [3]. - The global pharmaceutical industry is expected to see continued growth differentiation, with only Eli Lilly providing a double-digit revenue growth forecast for 2026 [3]. Group 3: Competition for the "King of Drugs" Title - In 2025, Eli Lilly's Tirzepatide secured the title of "King of Drugs" with a revenue contribution of $36.5 billion, while Merck's Keytruda generated $31.68 billion, marking a 7% increase [6][7]. - Novo Nordisk's Semaglutide followed closely with $36.1 billion in sales, reflecting over 10% growth [7]. - The GLP-1 drug market is becoming increasingly competitive, with both Eli Lilly and Novo Nordisk dominating the landscape [8]. Group 4: Performance in the Chinese Market - AstraZeneca maintained its leading position in the Chinese market with a revenue of $6.654 billion, representing a 4% increase [12]. - Roche and Novartis were among the top three companies in terms of revenue growth in China, with Roche achieving a 10% increase [13]. - Companies are increasingly focusing on local partnerships and innovations to enhance their market presence in China [14]. Group 5: Patent Expiration and New Growth Opportunities - Many multinational pharmaceutical companies are facing significant risks due to impending patent expirations, with some companies exposed to risks as high as 70% [16]. - The industry is witnessing a surge in business development activities, with 142 innovative drug transactions reported in 2025, marking a new high [17]. - Companies are increasingly seeking new growth avenues through mergers, acquisitions, and collaborations to mitigate the impact of patent cliffs [19].

Core Viewpoint - AbbVie is positioned strongly in the biopharmaceutical sector, particularly in the amylin class, supported by positive study results for its long-acting amylin analog, ABBV-295 [1][2]. Group 1: Study Results - AbbVie announced positive topline results from its Phase 1 study of ABBV-295, showing body weight reductions between 7.75% and 9.79% at week 12 with weekly dosing [2]. - The study indicated a favorable tolerability profile for ABBV-295, with no serious adverse events reported, and mild gastrointestinal disorders being the most common adverse events [3]. Group 2: Stock Performance - Despite positive study results, AbbVie's stock price decreased by 2.22% to $225.01, with a market capitalization of approximately $397.86 billion [4]. - The stock has experienced volatility over the past year, with a high of $244.81 and a low of $164.39 [4]. Group 3: Investor Interest - AbbVie's trading volume on the NYSE is about 4.05 million shares, indicating active investor interest [5]. - The ongoing development of ABBV-295, with doses ranging from 2 to 14 mg, reflects the company's commitment to advancing treatments in the amylin class [5].

action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, whi ...